Cortisol/progesterone antagonism in regulation of 15-hydroxysteroid dehydrogenase activity and mRNA levels in human chorion and placental trophoblast cells at term.
PGs mediate parturition events. 15-Hydroxyprostaglandin dehydrogenase (PGDH) catalyzes the first step in the metabolism of PGs to render them inactive. We have reported previously that cortisol (F) decreases PGDH activity and progesterone (P(4)) maintains PGDH in human chorion and placenta at term. To study the interaction of P(4) and F on the regulation of PGDH, we treated chorion and placental trophoblast cells in culture with combinations of F, dexamethasone, P(4), trilostane, and medroxyprogesterone acetate (MPA). Following a 24-h steroid treatment period and 4-h PGF(2alpha) challenge, culture media and cells were collected for measurement of PGF(2alpha) levels and PGDH mRNA by RIA and Northern blotting analysis. F and dexamethasone decreased PGDH activity and mRNA levels. Exogenous P(4) did not significantly alter PGDH activity or mRNA levels; however, MPA significantly stimulated PGDH activity. Trilostane decreased P(4) production by more than 90% and also decreased PGDH activity and expression. Coincubation with P(4) or MPA reversed trilostane inhibition of PGDH, consistent with a stimulatory role for endogenous P(4) on PGDH. MPA significantly reversed F inhibition of PGDH activity and mRNA levels. In the presence of trilostane, P(4) at equimolar concentration to F reversed F inhibition of PGDH mRNA levels. These findings suggest that F may be acting as an endogenous inhibitor of P(4) action in the regulation of PGDH at term.
Patel
Falguni A
FA
Canadian Institutes for Health Research Group in Fetal and Neonatal Health and Development, Department of Physiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada. fal.patel@utoronto.ca
Challis
John R G
JR
D002823:Chorion / Q000378:metabolism*; D046508:Culture Techniques; D013196:Dihydrotestosterone / Q000031:analogs & derivatives / Q000494:pharmacology; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D005865:Gestational Age; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology*; D006911:Hydroxyprostaglandin Dehydrogenases / Q000235:genetics* / Q000378:metabolism*; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology; D010920:Placenta / Q000378:metabolism*; D011247:Pregnancy; D011374:Progesterone / Q000494:pharmacology*; D045167:Progesterone Congeners / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism*; D014327:Trophoblasts / Q000166:cytology / Q000378:metabolism*
D004791:Enzyme Inhibitors; D005938:Glucocorticoids; D045167:Progesterone Congeners; D011372:Progestins; D012333:RNA, Messenger; D013196:Dihydrotestosterone; D011374:Progesterone; D017258:Medroxyprogesterone Acetate; D006911:Hydroxyprostaglandin Dehydrogenases; C035859:15-hydroxyprostaglandin dehydrogenase; C009954:trilostane; D006854:Hydrocortisone